Literature DB >> 18620706

Blockade of NF-kappaB using IkappaB alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice.

David Young1, Zoran B Popovic, W Keith Jones, Sudhiranjan Gupta.   

Abstract

Nuclear factor-kappaB (NF-kappaB) is a ubiquitous transcription factor that regulates various kinds of genes including inflammatory molecules, macrophage infiltration factors, cell adhesion molecules, and so forth, in various disease processes including cardiac hypertrophy and heart failure. Previously, we have demonstrated that activation of NF-kappaB was required in myotrophin-induced cardiac hypertrophy, in spontaneously hypertensive rats, and in dilated cardiomyopathy human hearts. Moreover, our recent study using the myotrophin-overexpressed transgenic mouse (Myo-Tg) model showed that short hairpin RNA-mediated knockdown of NF-kappaB significantly attenuated cardiac mass associated with improved cardiac function. Although it has been shown that NF-kappaB is substantially involved in cardiovascular remodeling, it is not clear whether the continuous blockade of NF-kappaB is effective in cardiovascular remodeling. To address this question, we took a genetic approach using IkappaB alpha triple mutant mice (3M) bred with Myo-Tg mice (a progressive hypertrophy/heart failure model). The double transgenic mice (Myo-3M) displayed an attenuated cardiac hypertrophy (9.8+/-0.62 versus 5.4+/-0.34, p<0.001) and improved cardiac function associated with significant inhibition of the NF-kappaB signaling cascade, hypertrophy marker gene expression, and inflammatory and macrophage gene expression at 24 weeks of age compared to Myo-Tg mice. NF-kappaB-targeted gene array profiling displayed several important genes that were significantly downregulated in Myo-3M mice compared to Myo-Tg mice. Furthermore, Myo-3M did not show any changes of apoptotic gene expression, indicating that significant inhibition of NF-kappaB activation reduces further proinflammatory reactions without affecting susceptibility to apoptosis. Therefore, development of therapeutic strategies targeting NF-kappaB may provide an effective approach to prevent adverse cardiac pathophysiological consequences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18620706      PMCID: PMC2688722          DOI: 10.1016/j.jmb.2008.05.076

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  46 in total

1.  Nuclear factor-kappaB and cell survival: IAPs call for support.

Authors:  R Lee; T Collins
Journal:  Circ Res       Date:  2001-02-16       Impact factor: 17.367

2.  Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction.

Authors:  Shunichi Kawano; Toru Kubota; Yoshiya Monden; Takaki Tsutsumi; Takahiro Inoue; Natsumi Kawamura; Hiroyuki Tsutsui; Kenji Sunagawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-04-21       Impact factor: 4.733

Review 3.  NF-kappaB in cardiovascular disease: diverse and specific effects of a "general" transcription factor?

Authors:  W Keith Jones; Maria Brown; Michael Wilhide; Suiwen He; Xiaoping Ren
Journal:  Cardiovasc Toxicol       Date:  2005       Impact factor: 3.231

Review 4.  Pathophysiological role of cytokines in congestive heart failure.

Authors:  A Blum; H Miller
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

5.  Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure.

Authors:  Stephan Schiekofer; Ichiro Shiojima; Kaori Sato; Gennaro Galasso; Yuichi Oshima; Kenneth Walsh
Journal:  Physiol Genomics       Date:  2006-08-01       Impact factor: 3.107

6.  Expression of relB is required for the development of thymic medulla and dendritic cells.

Authors:  L Burkly; C Hession; L Ogata; C Reilly; L A Marconi; D Olson; R Tizard; R Cate; D Lo
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

7.  Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha.

Authors:  Yoshihiro Higuchi; Tung O Chan; Maria A Brown; Jin Zhang; Brent R DeGeorge; Hajime Funakoshi; Gregory Gibson; Charles F McTiernan; Toru Kubota; W Keith Jones; Arthur M Feldman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-30       Impact factor: 4.733

8.  Quantification of myotrophin from spontaneously hypertensive and normal rat hearts.

Authors:  P Sil; D Mukherjee; S Sen
Journal:  Circ Res       Date:  1995-06       Impact factor: 17.367

9.  Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB.

Authors:  Sudhiranjan Gupta; David Young; Ratan K Maitra; Anasuya Gupta; Zoran B Popovic; Sandro L Yong; Anjuli Mahajan; Qing Wang; Subha Sen
Journal:  J Mol Biol       Date:  2007-10-10       Impact factor: 5.469

10.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B.

Authors:  A A Beg; W C Sha; R T Bronson; S Ghosh; D Baltimore
Journal:  Nature       Date:  1995-07-13       Impact factor: 49.962

View more
  22 in total

Review 1.  Is CaMKII a link between inflammation and hypertrophy in heart?

Authors:  Madhu V Singh; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

2.  Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.

Authors:  Qinghang Liu; Yi Chen; Mannix Auger-Messier; Jeffery D Molkentin
Journal:  Circ Res       Date:  2012-03-08       Impact factor: 17.367

3.  Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks.

Authors:  Sathyamangla V Naga Prasad; Zhong-Hui Duan; Manveen K Gupta; Venkata Suresh K Surampudi; Stefano Volinia; George A Calin; Chang-Gong Liu; Ashwin Kotwal; Christine S Moravec; Randall C Starling; Dianne M Perez; Subha Sen; Qingyu Wu; Edward F Plow; Carlo M Croce; Sadashiva Karnik
Journal:  J Biol Chem       Date:  2009-07-29       Impact factor: 5.157

4.  NF-κB-mediated miR-30b regulation in cardiomyocytes cell death by targeting Bcl-2.

Authors:  Chuanyu Wei; Li Li; Sudhiranjan Gupta
Journal:  Mol Cell Biochem       Date:  2013-11-01       Impact factor: 3.396

5.  Regulation of nuclear factor κB (NF-κB) in the nucleus of cardiomyocytes by G protein-coupled receptor kinase 5 (GRK5).

Authors:  Kazi N Islam; Jang-Whan Bae; Erhe Gao; Walter J Koch
Journal:  J Biol Chem       Date:  2013-10-29       Impact factor: 5.157

6.  AT1 receptor blockage impairs NF-κB activation mediated by thyroid hormone in cardiomyocytes.

Authors:  Ana Paula Cremasco Takano; Nathalia Senger; Carolina Demarchi Munhoz; Maria Luiza Morais Barreto-Chaves
Journal:  Pflugers Arch       Date:  2017-11-25       Impact factor: 3.657

7.  miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression.

Authors:  Yan Li; Xuejuan Xu; Ying Liang; Shanying Liu; Huisheng Xiao; Feng Li; Hua Cheng; Zuzhi Fu
Journal:  Int J Clin Exp Pathol       Date:  2010-01-25

8.  Do multiple nuclear factor kappa B activation mechanisms explain its varied effects in the heart?

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas
Journal:  Ochsner J       Date:  2013

9.  NEMO nuances NF-kappaB.

Authors:  Andriy Nemchenko; Joseph A Hill
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

10.  Cardiac-specific suppression of NF-κB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system.

Authors:  Candice M Thomas; Qian Chen Yong; Rodolfo M Rosa; Rachid Seqqat; Shanthi Gopal; Dulce E Casarini; W Keith Jones; Sudhiranjan Gupta; Kenneth M Baker; Rajesh Kumar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-01       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.